CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 63 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,404,920 | -58.8% | 476,634 | -40.0% | 0.12% | -59.3% |
| Q2 2023 | $25,270,475 | +69.5% | 794,919 | +30.0% | 0.30% | +47.8% |
| Q1 2023 | $14,911,217 | +1.8% | 611,366 | +31.6% | 0.20% | +3.6% |
| Q4 2022 | $14,647,428 | -3.4% | 464,408 | -13.4% | 0.20% | -7.5% |
| Q3 2022 | $15,158,000 | +124.4% | 536,385 | +109.9% | 0.21% | +103.8% |
| Q2 2022 | $6,756,000 | -46.7% | 255,533 | -29.4% | 0.10% | -49.5% |
| Q1 2022 | $12,665,000 | +64.6% | 361,753 | +52.4% | 0.21% | +87.3% |
| Q4 2021 | $7,694,000 | +33.5% | 237,326 | +21.5% | 0.11% | +17.0% |
| Q3 2021 | $5,762,000 | +56.5% | 195,331 | +35.9% | 0.09% | +36.2% |
| Q2 2021 | $3,682,000 | -31.8% | 143,712 | -63.4% | 0.07% | -42.5% |
| Q1 2021 | $5,395,000 | – | 392,910 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,005,284,000 | 38.09% |
| Ally Bridge Group (NY) LLC | 1,767,440 | $29,304,000 | 5.02% |
| Affinity Asset Advisors, LLC | 270,000 | $4,477,000 | 2.37% |
| SPHERA FUNDS MANAGEMENT LTD. | 811,665 | $13,457,000 | 1.19% |
| Artal Group S.A. | 2,282,100 | $37,837,000 | 0.81% |
| Perceptive Advisors | 4,544,062 | $75,340,000 | 0.81% |
| RA Capital Management | 2,200,000 | $36,476,000 | 0.51% |
| Monashee Investment Management LLC | 200,000 | $3,316,000 | 0.44% |
| Boxer Capital, LLC | 714,500 | $11,846,000 | 0.38% |
| EcoR1 Capital, LLC | 400,000 | $6,632,000 | 0.36% |